JP5511095B2 - ゾル粒子特異的結合アッセイの多波長分析 - Google Patents
ゾル粒子特異的結合アッセイの多波長分析 Download PDFInfo
- Publication number
- JP5511095B2 JP5511095B2 JP2011500931A JP2011500931A JP5511095B2 JP 5511095 B2 JP5511095 B2 JP 5511095B2 JP 2011500931 A JP2011500931 A JP 2011500931A JP 2011500931 A JP2011500931 A JP 2011500931A JP 5511095 B2 JP5511095 B2 JP 5511095B2
- Authority
- JP
- Japan
- Prior art keywords
- reagent
- wavelength
- absorbance
- group
- value
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000002245 particle Substances 0.000 title claims description 38
- 230000009870 specific binding Effects 0.000 title description 8
- 238000004458 analytical method Methods 0.000 title description 4
- 238000000159 protein binding assay Methods 0.000 title description 3
- 238000002835 absorbance Methods 0.000 claims description 253
- 239000003153 chemical reaction reagent Substances 0.000 claims description 239
- 238000006243 chemical reaction Methods 0.000 claims description 205
- 238000000034 method Methods 0.000 claims description 139
- 230000031700 light absorption Effects 0.000 claims description 83
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 48
- 239000012491 analyte Substances 0.000 claims description 46
- 229910052737 gold Inorganic materials 0.000 claims description 45
- 239000010931 gold Substances 0.000 claims description 45
- 238000002156 mixing Methods 0.000 claims description 36
- 238000005259 measurement Methods 0.000 claims description 26
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 24
- 238000000862 absorption spectrum Methods 0.000 claims description 23
- 239000002078 nanoshell Substances 0.000 claims description 21
- 239000012472 biological sample Substances 0.000 claims description 19
- 241000282465 Canis Species 0.000 claims description 18
- 229910052751 metal Inorganic materials 0.000 claims description 17
- 239000002184 metal Substances 0.000 claims description 17
- 239000002082 metal nanoparticle Substances 0.000 claims description 13
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 12
- 239000000377 silicon dioxide Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 208000016604 Lyme disease Diseases 0.000 claims description 10
- 238000002834 transmittance Methods 0.000 claims description 10
- 241000589968 Borrelia Species 0.000 claims description 9
- 241000606646 Anaplasma Species 0.000 claims description 7
- 241000589969 Borreliella burgdorferi Species 0.000 claims description 7
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 7
- 241000714165 Feline leukemia virus Species 0.000 claims description 7
- 241000589248 Legionella Species 0.000 claims description 7
- 208000007764 Legionnaires' Disease Diseases 0.000 claims description 7
- 241000125945 Protoparvovirus Species 0.000 claims description 7
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 7
- 239000010949 copper Substances 0.000 claims description 7
- 229910052802 copper Inorganic materials 0.000 claims description 7
- 208000037797 influenza A Diseases 0.000 claims description 7
- 208000037798 influenza B Diseases 0.000 claims description 7
- 229910052709 silver Inorganic materials 0.000 claims description 7
- 239000004332 silver Substances 0.000 claims description 7
- 241000701161 unidentified adenovirus Species 0.000 claims description 7
- 241000712461 unidentified influenza virus Species 0.000 claims description 7
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 6
- 229910052697 platinum Inorganic materials 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000011246 composite particle Substances 0.000 claims description 5
- 241000238631 Hexapoda Species 0.000 claims description 4
- 241001505901 Streptococcus sp. 'group A' Species 0.000 claims description 4
- 241001148604 Borreliella afzelii Species 0.000 claims description 3
- 241001148605 Borreliella garinii Species 0.000 claims description 3
- 241000605312 Ehrlichia canis Species 0.000 claims description 3
- 229940051998 ehrlichia canis Drugs 0.000 claims description 3
- 241000605281 Anaplasma phagocytophilum Species 0.000 claims description 2
- 239000000126 substance Substances 0.000 claims description 2
- 230000008859 change Effects 0.000 description 72
- 239000000523 sample Substances 0.000 description 56
- 239000000427 antigen Substances 0.000 description 43
- 108091007433 antigens Proteins 0.000 description 42
- 102000036639 antigens Human genes 0.000 description 42
- 239000000562 conjugate Substances 0.000 description 32
- 239000002105 nanoparticle Substances 0.000 description 27
- 239000013068 control sample Substances 0.000 description 25
- 238000001514 detection method Methods 0.000 description 21
- 239000000243 solution Substances 0.000 description 20
- 230000027455 binding Effects 0.000 description 15
- 230000010354 integration Effects 0.000 description 15
- 238000003556 assay Methods 0.000 description 14
- 238000001228 spectrum Methods 0.000 description 14
- 230000003287 optical effect Effects 0.000 description 13
- 230000009257 reactivity Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 239000011324 bead Substances 0.000 description 10
- 238000004364 calculation method Methods 0.000 description 10
- 230000007423 decrease Effects 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 6
- 238000004220 aggregation Methods 0.000 description 6
- 229940127121 immunoconjugate Drugs 0.000 description 6
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000011481 absorbance measurement Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000012723 sample buffer Substances 0.000 description 3
- 238000001179 sorption measurement Methods 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 241001481710 Cerambycidae Species 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000005855 radiation Effects 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 241000255789 Bombyx mori Species 0.000 description 1
- 241000243988 Dirofilaria immitis Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- 208000004023 Legionellosis Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 1
- XEIPQVVAVOUIOP-UHFFFAOYSA-N [Au]=S Chemical compound [Au]=S XEIPQVVAVOUIOP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000006730 anaplasmosis Diseases 0.000 description 1
- -1 antibodies Proteins 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012496 blank sample Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000002772 conduction electron Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 229940099686 dirofilaria immitis Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000054 fungal extract Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 239000011133 lead Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005976 liver dysfunction Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
- G01N33/587—Nanoparticles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/31—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
- G01N21/314—Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry with comparison of measurements at specific and non-specific wavelengths
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
- G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/25—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
- G01N21/27—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration
- G01N21/272—Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection ; circuits for computing concentration for following a reaction, e.g. for determining photometrically a reaction rate (photometric cinetic analysis)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Nanotechnology (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3832408P | 2008-03-20 | 2008-03-20 | |
| US61/038,324 | 2008-03-20 | ||
| US9841708P | 2008-09-19 | 2008-09-19 | |
| US61/098,417 | 2008-09-19 | ||
| PCT/US2009/037553 WO2009117510A2 (en) | 2008-03-20 | 2009-03-18 | Multi-wavelength analyses of sol-particle specific binding assays |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014033833A Division JP6050772B2 (ja) | 2008-03-20 | 2014-02-25 | ゾル粒子特異的結合アッセイの多波長分析 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525966A JP2011525966A (ja) | 2011-09-29 |
| JP2011525966A5 JP2011525966A5 (enExample) | 2012-05-17 |
| JP5511095B2 true JP5511095B2 (ja) | 2014-06-04 |
Family
ID=41091521
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011500931A Active JP5511095B2 (ja) | 2008-03-20 | 2009-03-18 | ゾル粒子特異的結合アッセイの多波長分析 |
| JP2014033833A Active JP6050772B2 (ja) | 2008-03-20 | 2014-02-25 | ゾル粒子特異的結合アッセイの多波長分析 |
| JP2016015506A Pending JP2016106223A (ja) | 2008-03-20 | 2016-01-29 | ゾル粒子特異的結合アッセイの多波長分析 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014033833A Active JP6050772B2 (ja) | 2008-03-20 | 2014-02-25 | ゾル粒子特異的結合アッセイの多波長分析 |
| JP2016015506A Pending JP2016106223A (ja) | 2008-03-20 | 2016-01-29 | ゾル粒子特異的結合アッセイの多波長分析 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US8137920B2 (enExample) |
| EP (1) | EP2265947A4 (enExample) |
| JP (3) | JP5511095B2 (enExample) |
| WO (1) | WO2009117510A2 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101392106B1 (ko) | 2005-05-09 | 2014-05-07 | 테라노스, 인코포레이티드 | 현장진료 유체 시스템 및 그 용도 |
| US11287421B2 (en) | 2006-03-24 | 2022-03-29 | Labrador Diagnostics Llc | Systems and methods of sample processing and fluid control in a fluidic system |
| US8741230B2 (en) | 2006-03-24 | 2014-06-03 | Theranos, Inc. | Systems and methods of sample processing and fluid control in a fluidic system |
| US8007999B2 (en) | 2006-05-10 | 2011-08-30 | Theranos, Inc. | Real-time detection of influenza virus |
| US8012744B2 (en) | 2006-10-13 | 2011-09-06 | Theranos, Inc. | Reducing optical interference in a fluidic device |
| US8158430B1 (en) | 2007-08-06 | 2012-04-17 | Theranos, Inc. | Systems and methods of fluidic sample processing |
| BR122020017678B1 (pt) | 2007-10-02 | 2021-08-03 | Labrador Diagnostics Llc | Sistema para detecção automática de um analito em uma amostra de fluido corporal |
| US8137920B2 (en) * | 2008-03-20 | 2012-03-20 | Abaxis, Inc. | Multi-wavelength analyses of sol-particle specific binding assays |
| CN105740641A (zh) | 2009-10-19 | 2016-07-06 | 提拉诺斯公司 | 集成的健康数据采集和分析系统 |
| KR20120107497A (ko) | 2009-12-17 | 2012-10-02 | 아박시스, 인크. | 샘플 내 분석물을 검출하기 위한 신규 분석 및 그것과 관련된 키트 및 조성물 |
| WO2011147879A1 (en) * | 2010-05-27 | 2011-12-01 | Episentec Ab | Improved method of sensor measurement |
| MX2013008339A (es) | 2011-01-21 | 2014-02-11 | Theranos Inc | Sistemas y metodos para maximizacion de uso de muestras. |
| ES2702033T3 (es) * | 2011-11-21 | 2019-02-27 | Abay Sa | Amplificación de la señal en inmunoensayos |
| EP3006922B1 (en) * | 2013-05-31 | 2018-08-01 | Sekisui Medical Co., Ltd. | Method of agglutination immunoassay |
| EP2837937A1 (en) * | 2013-08-15 | 2015-02-18 | Roche Diagniostics GmbH | Method for the detection of the prozone effect of photometric assays |
| TWI691716B (zh) | 2014-08-13 | 2020-04-21 | 美商艾巴希斯公司 | 電漿特異性結合搭配物檢定中之信號放大 |
| EP3001183B1 (en) * | 2014-09-25 | 2019-02-13 | Centre National De La Recherche Scientifique (Cnrs) | Detection of analytes using nanoparticles as light scattering enhancers |
| WO2016208466A1 (ja) * | 2015-06-22 | 2016-12-29 | ウシオ電機株式会社 | 検出対象物質の検出方法 |
| AU2016301375B2 (en) | 2015-08-04 | 2022-03-03 | Zoetis Services Llc | Signal amplification in solution-based plasmonic specific-binding partner assays |
| JP6507969B2 (ja) * | 2015-09-25 | 2019-05-08 | コニカミノルタ株式会社 | ガス検知方法及びガス検知装置 |
| JP7308148B2 (ja) | 2017-01-30 | 2023-07-13 | ゾエティス サービシズ リミテッド ライアビリティ カンパニー | 溶液ベースのプラズモン特異的結合パートナーアッセイおよび金属ナノ構造体 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH06105256B2 (ja) * | 1983-06-14 | 1994-12-21 | 株式会社東芝 | 免疫分析方法 |
| US5093271A (en) * | 1986-11-28 | 1992-03-03 | Shimadzu Corporation | Method for the quantitative determination of antigens and antibodies by ratio of absorbances at different wavelengths |
| JPS63149565A (ja) * | 1986-12-12 | 1988-06-22 | Sekisui Chem Co Ltd | 免疫測定法 |
| US4954435A (en) * | 1987-01-12 | 1990-09-04 | Becton, Dickinson And Company | Indirect colorimetric detection of an analyte in a sample using ratio of light signals |
| JP3496684B2 (ja) * | 1992-09-09 | 2004-02-16 | 和光純薬工業株式会社 | 金コロイド粒子を用いた比色分析法 |
| US6699724B1 (en) * | 1998-03-11 | 2004-03-02 | Wm. Marsh Rice University | Metal nanoshells for biosensing applications |
| JP3695178B2 (ja) * | 1998-11-04 | 2005-09-14 | 三菱化学株式会社 | 抗原・抗体の測定方法 |
| EP1072887B1 (en) * | 1999-07-30 | 2005-11-16 | Mitsubishi Chemical Corporation | Immunoassay |
| US8043868B2 (en) * | 2001-12-21 | 2011-10-25 | Imec | Method and apparatus for detecting an analyte |
| JP2005283250A (ja) * | 2004-03-29 | 2005-10-13 | Alfresa Pharma Corp | 金コロイド凝集反応の測定方法 |
| JP2007023384A (ja) * | 2005-07-08 | 2007-02-01 | Dai Ichi Pure Chem Co Ltd | 金コロイドの粒径調整方法及び金コロイド溶液 |
| EP2947094B1 (en) * | 2007-09-13 | 2018-11-14 | Temasek Life Sciences Laboratory Limited | Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof |
| US8137920B2 (en) * | 2008-03-20 | 2012-03-20 | Abaxis, Inc. | Multi-wavelength analyses of sol-particle specific binding assays |
-
2009
- 2009-03-18 US US12/406,906 patent/US8137920B2/en active Active
- 2009-03-18 EP EP20090721836 patent/EP2265947A4/en not_active Withdrawn
- 2009-03-18 WO PCT/US2009/037553 patent/WO2009117510A2/en not_active Ceased
- 2009-03-18 JP JP2011500931A patent/JP5511095B2/ja active Active
-
2012
- 2012-03-19 US US13/424,217 patent/US8673576B2/en active Active
-
2014
- 2014-02-25 JP JP2014033833A patent/JP6050772B2/ja active Active
-
2016
- 2016-01-29 JP JP2016015506A patent/JP2016106223A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2265947A4 (en) | 2011-03-30 |
| EP2265947A2 (en) | 2010-12-29 |
| US20120252005A1 (en) | 2012-10-04 |
| JP2016106223A (ja) | 2016-06-16 |
| US8673576B2 (en) | 2014-03-18 |
| US20100159441A1 (en) | 2010-06-24 |
| WO2009117510A2 (en) | 2009-09-24 |
| WO2009117510A3 (en) | 2009-12-10 |
| JP6050772B2 (ja) | 2016-12-21 |
| US8137920B2 (en) | 2012-03-20 |
| JP2014139571A (ja) | 2014-07-31 |
| JP2011525966A (ja) | 2011-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6050772B2 (ja) | ゾル粒子特異的結合アッセイの多波長分析 | |
| JP6367942B2 (ja) | 測光アッセイのプロゾーン効果の検出方法 | |
| US10036750B2 (en) | Immunochromatography, and detection device and reagent for the same | |
| EP3321666B1 (en) | Thermal contrast assay and reader | |
| JP5539958B2 (ja) | 薄膜状体液試料において実施される血清学的凝集イムノアッセイ及び他のイムノアッセイのための方法 | |
| JP6298043B2 (ja) | 自動分析計で流体試料中の被検体の量を測光法により決定するためのマルチアプリケーション法 | |
| US8530152B2 (en) | Methods of reducing non-specific interaction in metal nanoparticle assays | |
| KR101718485B1 (ko) | 면역크로마토그래피의 형광반응 또는 유색반응을 측정하기 위한 디바이스 | |
| WO2011096394A1 (ja) | アナライト検出プローブおよびこれを用いたアナライトの検出方法 | |
| JP4331073B2 (ja) | 抗原の測定方法及びそのための試薬 | |
| JPS6365369A (ja) | 抗原−抗体反応の測定法 | |
| EP2905617B1 (en) | Immunoassay method and system utilizing surface plasmons | |
| KR101787791B1 (ko) | 시료 중의 분석 대상 물질을 측정하기 위한 검사 기구 및 그것을 사용한 분석 대상 물질의 측정 방법 | |
| EP1742037A1 (en) | Process to adjust the particle size in the preparation of colloidal gold | |
| GB1600139A (en) | Method and apparatus for the measurement of antigens and antibodies | |
| Kim et al. | Development of a High-performance COVID-19 Diagnostic Kit Employing Improved Antibody-quantum dot Conjugate | |
| JPH01270643A (ja) | 検体検査方法 | |
| JPH0599925A (ja) | 抗原または抗体の濃度の測定方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120319 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20120319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130710 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130710 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131009 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131017 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131031 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20131202 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140225 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140319 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140324 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5511095 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |